SPS
FDMT icon

Susquehanna Portfolio Strategies’s 4D Molecular Therapeutics FDMT Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Buy
106,935
+78,439
+275% +$764K 0.02% 498
2026
Q1 		$265K Buy
28,496
+18,186
+176% +$158K ﹤0.01% 860
2025
Q4 		$77.3K Buy
+10,310
New +$105K ﹤0.01% 983

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Susquehanna Portfolio Strategies's FDMT Position: Q2 2026 in Review

Susquehanna Portfolio Strategies increased its 4D Molecular Therapeutics (FDMT) stake by 275% in Q2 2026, buying an estimated $764K and bringing the position to 106,935 shares worth $1.42M. The position accounts for 0.02% of the portfolio, ranked #498.

Susquehanna Portfolio Strategies first reported a position in FDMT in Q4 2025 and has held it in 3 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Susquehanna Portfolio Strategies held 106,935 shares of 4D Molecular Therapeutics worth $1.42M as of Q2 2026.
  • Susquehanna Portfolio Strategies bought 78,439 4D Molecular Therapeutics shares in Q2 2026, an estimated $764K.
  • 4D Molecular Therapeutics made up 0.02% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #498 holding.
  • Susquehanna Portfolio Strategies first reported a position in 4D Molecular Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.